1. ABRpresto: An algorithm for automatic thresholding of the Auditory Brainstem Response using resampled cross-correlation across subaverages.
- Author
-
Shaheen LA, Buran BN, Suthakar K, Koehler SD, and Chung Y
- Abstract
The auditory brainstem response (ABR) is an essential diagnostic indicator of overall cochlear health, used extensively in both basic research and clinical studies. A key quantification of the ABR is threshold, the lowest sound level that elicits a response. Because the morphology of ABR waveforms shift with stimulus level and the overall signal-to-noise ratio is low, threshold estimation is not straightforward. Although several algorithmic approaches have been proposed, the current standard practice remains the visual evaluation of ABR waveforms as a function of stimulus level. We developed an algorithm based on the cross-correlation of two independent averages of responses to the same stimulus. For each stimulus level, the individual responses to each tone-pip are randomly split into two groups. The median waveform for each group is calculated, and then the normalized cross-correlation between these median waveforms is obtained. This process is repeated 500 times to obtain a resampled cross-correlation distribution. For each frequency, the mean values of these distributions are computed for each level and fit with a sigmoid or a power law function to estimate the threshold. Algorithmic thresholds demonstrated robust and accurate performance, achieving 92% accuracy within ±10 dB of human-rated thresholds on a large pool of mouse data. This performance was better than that of several published algorithms on the same dataset. This algorithm has now fully replaced the manual estimation of ABR thresholds for our preclinical studies, thereby saving significant time and enhancing objectivity in the process., Competing Interests: Declaration of interests Luke Shaheen, Seth Koehler, and Yoojin Chung were employees of Decibel Therapeutics or Regeneron Pharmaceuticals at the time of contribution to this publication and may hold company stock and/or stock options. Brad Buran was a paid consultant for Decibel Therapeutics or Regeneron Pharmaceuticals at the time of contribution to this publication.
- Published
- 2024
- Full Text
- View/download PDF